Family Medicine Doctors in Hill City, KS Accepting Medicare
4 Family Medicine doctors found. Showing 1 - 4
 David Lynd Atkins, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 114 E Walnut St, Hill City, KS 67642 Phone: 785-421-2191 Fax: 785-421-2195 |
Dr. Padala J. Reddy, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 114 E Walnut St, Hill City, KS 67642 Phone: 785-421-2191 Fax: 785-421-2195 |
Dr. Bollam N. Reddy, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 114 E Walnut St, Hill City, KS 67642 Phone: 785-421-2191 Fax: 785-421-2195 |
Dr. Luke Anthony Handy, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 114 E Walnut St, Hill City, KS 67642 Phone: 785-421-2191 |
News Archive
Roundup: In Oregon, New Gov. Kitzhaber vows to change state's health care delivery system; In Ariz., 2nd person denied transplant coverage dies
Oregon Governor-elect John Kitzhaber, a Democrat who will be inaugurated in Salem on Monday (January 10), is no stranger to the state's top political office: He was a two-term governor between 1995 and 2003. ... An emergency-room physician by background, Kitzhaber, 62, also is no stranger to the nation's health care system, which he sees as costly, ineffective and unsustainable.
Firing doctor, Christian hospital sets off national challenge to aid-in-dying laws
Centura Health Corp. this week abruptly terminated Dr. Barbara Morris, 65, a geriatrician with 40 years of experience, who had planned to help her patient, Cornelius "Neil" Mahoney, 64, end his life at his home. Mahoney, who has terminal cancer, is eligible to use the state's law, overwhelmingly approved by Colorado voters in 2016.
Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
Researchers reanalyze COVID RECOVERY trial data on tocilizumab
A Bayesian analysis of the RECOVERY trial suggests the immunosuppressive drug tocilizumab can reduce deaths in hospitalized COVID-19 patients taking corticosteroids as well as patients on oxygen or non-invasive ventilation and likely increases hospital discharge rates. However, it is not clear if patients on invasive ventilation also benefit.
Pelvic mesh implantation horrors
Thousands of women undergo operations to get pelvic meshes inserted surgically within their lower bodies to prevent prolapsing of the abdominal organs after childbirth complications.
› Verified 9 days ago